2.25 / AMA PRA Category 1 Credit(s)TM 2.25 / CNE Contact Hours
This activity is jointly provided by Medical Education Resources, Inc., and Veritas Institute for Medical Education, Inc.
Supported by an educational grant from Spectrum Pharmaceuticals
Peripheral T-cell lymphomas (PTCLs) are a group of rare and usually aggressive non-Hodgkin lymphomas (NHLs) that develop from mature T-cells and account for 10% of all NHL cases in the United States.1 Despite advances in available treatment options, prognosis for PTCL remains poor compared to B-cell NHL, mostly due to poorer response rates and less durable responses to standard combination chemotherapy regimens.2 Individualized treatment and patient selection for the appropriate treatment approach in PTCL can be problematic especially for the community oncologist due to the rarity of PTCL. This unique case-based activity is designed to provide education to community oncologists that will highlight important issues in treating PTCL, which ultimately will improve patient outcomes.
References 1. Swerdlow SH, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008:262-268. 2. Zelenetz AD, Gordon LI, Wierda WG, et al. Non-Hodgkin's lymphomas, version 4.2014. J Natl Compr Canc Netw. 2014;12(9):1282-1303.
This activity has been designed to meet the educational needs of community hematologists/oncologists and other healthcare professionals involved in the care of patients with PTCL.
Upon completion of this activity, participants should be able to:
Discuss front-line therapy options for PTCL and the role of transplant in this setting
Describe special considerations in PTCL therapy options for elderly patients and those with comorbidities
Evaluate the role of newer agents for relapsed/refractory PTCL
Discuss the common side effects of available PTCL treatment options and strategies to manage these side effects
Conflict Of Interest Disclosure Policy
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Medical Education Resources is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Michelle Fanale, MD Associate Professor Department of Lymphoma/Myeloma Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, TX
Dr. Fanale discloses the following: Consulting fees (eg, ad boards): Amgen, Bristol-Myers Squibb, Spectrum Pharmaceuticals, Merck Grants/research support: Bristol-Myers Squibb, Celgene, Genentech, Gilead Sciences, MedImmune, Merck, Millennium, Novartis, Molecular Templates, Seattle Genetics Honoraria: Plexus, Research to Practice, Seattle Genetics, Takeda Travel expenses: Bristol-Myers Squibb, Merck, Plexus, Takeda, Research to Practice, Spectrum Pharmaceuticals
Francine Foss, MD Professor of Medicine Yale University School of Medicine New Haven, CT
Dr. Foss discloses the following: Consulting fees (eg, ad boards): Kyowa Kirin Pharmaceutical Development, Inc., miRagen Therapeutics Speakers’ bureau: Celegene Corporation, Seattle Genetics, Spectrum Pharmaceuticals
Owen A. O’Connor, MD, PhD Founding Director, Center for Lymphoid Malignancies Professor of Medicine and Developmental Therapeutics The New York Presbyterian Hospital Columbia University College of Physicians and Surgeons New York, NY
Dr. O’Connor discloses the following: Consulting fees (eg, ad boards): Spectrum Pharmaceuticals, Mundipharma, Servier Laboratories Grants/research support: Celgene Corporation, Spectrum Pharmaceuticals
Andrei Shustov, MD Associate Professor University of Washington School of Medicine Associate Member Fred Hutchinson Cancer Research Center Seattle, WA
Dr. Shustov discloses the following: Grants/research support: Spectrum Pharmaceuticals
Planners' and Managers' Disclosures
The staff of Veritas Institute for Medical Education, Inc., has nothing to disclose.
The content planners at Medical Education Resources have nothing to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Veritas Institute for Medical Education, Inc. Medical Education Resources is accredited by the ACCME to provide continuing medical education for physicians.
Medical Education Resources designates this enduring material for a maximum of 2.25 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Contact Hour(s)
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This CE activity provides 2.25 contact hours of continuing nursing education.
Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 2.25 contact hours.
Disclosure of Unlabeled Use
Participants are advised that this CME/CE activity will contain references to medication or medical device names which at present are not FDA-approved for use in PTCL.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Veritas Institute for Medical Education, Inc., and/or Spectrum Pharmaceuticals. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Medical Education Resources, Veritas Institute for Medical Education, Inc., and/or Spectrum Pharmaceuticals. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
For information about the accreditation of this program, please contact Susan Jones at MER: email@example.com.